Validation of the urgency perception scale

BJU International

Volumn 95, Issue 4, 2005, Pages 591-596

  Cardozo, Linda ^a   Coyne, Karin S ^a,b   Versi, Eboo ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Bladder; Muscarinic antagonist; Perception; Tolterodine; Urinary urgency; Validation

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DAILY LIFE ACTIVITY; DIAGNOSTIC VALUE; DRUG EFFICACY; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; OUTCOMES RESEARCH; OVERACTIVE BLADDER; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SHORT FORM 36; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; URGENCY PERCEPTION SCALE; URINARY URGENCY; VALIDATION PROCESS;

AGED; BENZHYDRYL COMPOUNDS; CRESOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PERCEPTION; PHENYLPROPANOLAMINE; QUALITY OF LIFE; SINGLE-BLIND METHOD; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 14144255467     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05345.x     Document Type: Article

References (19)

1. Abrams P, Wein AJ. The overactive bladder. A widespread and treatable condition. Stockholm: Erick Sparre Medical AB, 1998
2. Stewart W, VanRooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
3. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6: 5565-73
4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
5. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health 1999; 2: 113-27
6. Revicki DA, Osoba D, Fairclough D et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9: 887-900
7. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. New York, NY: McGraw-Hill Companies, 1994
8. Van Kerrebroeck P, Kreder K, Jonas U et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414-21
9. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24: 616-28
10. Groutz A, Blaivas JG, Chaikin DC et al. Noninvasive outcome measures for urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. J Urol 2000; 164: 698-701
11. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
12. Ware J, Snow K, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Centre, 1993
13. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. BJOG 1997; 104: 1374-9
14. Pleil AM, Reese PR, Kelleher CJ, Okano GJ. Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC 2001; 2: 69-75
15. Coyne KS, Revicki DA, Hunt TL et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563-74
16. Jaeschke R, Singer J, Guyatt GH. Measurements of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15
17. Cohen J. Statistical Power Analysis for the Behavioural Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988
18. Coyne KS, Bhattacharyya S, Revicki D, Thompson C, Corey R, Hunt TL. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health, in press
19. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78